These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 34374028)

  • 1. The Effect of Treatment Discontinuation During the COVID-19 Pandemic on Visual Acuity in Exudative Neovascular Age-Related Macular Degeneration: 1-Year Results.
    Stattin M; Ahmed D; Graf A; Haas AM; Kickinger S; Jacob M; Krepler K; Ansari-Shahrezaei S
    Ophthalmol Ther; 2021 Dec; 10(4):935-945. PubMed ID: 34374028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of a calculation model to estimate the impact of the COVID-19 pandemic lockdown on visual acuity in neovascular AMD.
    Stattin M; Haas AM; Ahmed D; Graf A; Krepler K; Ansari-Shahrezaei S
    Eur J Ophthalmol; 2022 Jul; 32(4):2312-2318. PubMed ID: 34726553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of the treatment of patients with exudative AMD during the COVID-19 pandemic.
    Arruabarrena C; Montejano-Milner R; de Aragón F; Allendes G; Teus MA
    Arch Soc Esp Oftalmol (Engl Ed); 2022 Apr; 97(4):184-190. PubMed ID: 35523464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term impact of delayed follow-up due to COVID-19 lockdown on patients with neovascular age-related macular degeneration.
    Szegedi S; Ebner C; Miháltz K; Wachter T; Vécsei-Marlovits PV
    BMC Ophthalmol; 2022 May; 22(1):228. PubMed ID: 35596203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Results of the treatment of patients with exudative AMD during the COVID-19 pandemic].
    Arruabarrena C; Montejano-Milner R; de Aragón F; Allendes G; Teus MA
    Arch Soc Esp Oftalmol; 2022 Apr; 97(4):184-190. PubMed ID: 34876774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact on Visual Acuity in Neovascular Age Related Macular Degeneration (nAMD) in Europe Due to COVID-19 Pandemic Lockdown.
    Arruabarrena C; Toro MD; Onen M; Malyugin BE; Rejdak R; Tognetto D; Zweifel S; Giglio R; Teus MA
    J Clin Med; 2021 Jul; 10(15):. PubMed ID: 34362066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of COVID-19 pandemic restrictions on neovascular AMD patients treated with treat-and-extend protocol.
    Sevik MO; Aykut A; Özkan G; Dericioğlu V; Şahin Ö
    Int Ophthalmol; 2021 Sep; 41(9):2951-2961. PubMed ID: 33864577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Seven-Year Visual and Anatomical Outcomes of Intravitreal Vascular Endothelial Growth Factor Inhibition for Neovascular Age-Related Macular Degeneration.
    Stattin M; Forster J; Ahmed D; Haas AM; Graf A; Krepler K; Ansari-Shahrezaei S
    J Ophthalmol; 2020; 2020():8345850. PubMed ID: 32211201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.
    Carrasco J; Pietsch GA; Nicolas MP; Koerber C; Bennison C; Yoon J
    Adv Ther; 2020 Jan; 37(1):300-315. PubMed ID: 31728825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defining response to anti-VEGF therapies in neovascular AMD.
    Amoaku WM; Chakravarthy U; Gale R; Gavin M; Ghanchi F; Gibson J; Harding S; Johnston RL; Kelly SP; Lotery A; Mahmood S; Menon G; Sivaprasad S; Talks J; Tufail A; Yang Y
    Eye (Lond); 2015 Jun; 29(6):721-31. PubMed ID: 25882328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Impact of the French 2020 COVID-19 lockdown on the treatment and follow-up of patients with exudative age-related macular degeneration].
    Auger A; Khanna RK; Bonicel P; Pisella PJ; Le Lez ML
    J Fr Ophtalmol; 2023 Jun; 46(6):596-604. PubMed ID: 37248127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SIERRA-AMD: A Retrospective, Real-World Evidence Study of Patients with Neovascular Age-Related Macular Degeneration in the United States.
    Khanani AM; Skelly A; Bezlyak V; Griner R; Torres LR; Sagkriotis A
    Ophthalmol Retina; 2020 Feb; 4(2):122-133. PubMed ID: 31812631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TEN-YEAR FOLLOW-UP OF PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS.
    Starr MR; Kung FF; Mejia CA; Bui YT; Bakri SJ
    Retina; 2020 Sep; 40(9):1665-1672. PubMed ID: 31725524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration.
    Brynskov T; Munch IC; Larsen TM; Erngaard L; Sørensen TL
    Acta Ophthalmol; 2020 Mar; 98(2):132-138. PubMed ID: 31282617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration.
    Peden MC; Suñer IJ; Hammer ME; Grizzard WS
    Ophthalmology; 2015 Apr; 122(4):803-8. PubMed ID: 25596618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Neovascular recurrences in 42 treatment-naive eyes with neovascular age-related macular degeneration (AMD) followed for over 2 years].
    Bodénès F; Massé H; Lebreton O; Weber M
    J Fr Ophtalmol; 2021 May; 44(5):626-631. PubMed ID: 33840491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fellow Eye Comparisons for 7-Year Outcomes in Ranibizumab-Treated AMD Subjects from ANCHOR, MARINA, and HORIZON (SEVEN-UP Study).
    Bhisitkul RB; Desai SJ; Boyer DS; Sadda SR; Zhang K
    Ophthalmology; 2016 Jun; 123(6):1269-77. PubMed ID: 26996339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macula service evaluation and assessing priorities for anti-VEGF treatment in the light of COVID-19.
    Stone LG; Devenport A; Stratton IM; Talks JS
    Graefes Arch Clin Exp Ophthalmol; 2020 Dec; 258(12):2639-2645. PubMed ID: 32712708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VITREOMACULAR TRACTION AFFECTS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OUTCOMES FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION.
    Krishnan R; Arora R; De Salvo G; Stinghe A; Severn PS; Pal B; Goverdhan S
    Retina; 2015 Sep; 35(9):1750-6. PubMed ID: 26237240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consistent Long-Term Therapy of Neovascular Age-Related Macular Degeneration Managed by 50 or More Anti-VEGF Injections Using a Treat-Extend-Stop Protocol.
    Adrean SD; Chaili S; Ramkumar H; Pirouz A; Grant S
    Ophthalmology; 2018 Jul; 125(7):1047-1053. PubMed ID: 29439828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.